Stereochemistry | ABSOLUTE |
Molecular Formula | C25H30N2O7 |
Molecular Weight | 470.5149 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC2=C(CN([C@@H](C2)C(O)=O)C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(O)=O)C=C1OC
InChI
InChIKey=CMPAGYDKASJORH-YSSFQJQWSA-N
InChI=1S/C25H30N2O7/c1-15(26-19(24(29)30)10-9-16-7-5-4-6-8-16)23(28)27-14-18-13-22(34-3)21(33-2)12-17(18)11-20(27)25(31)32/h4-8,12-13,15,19-20,26H,9-11,14H2,1-3H3,(H,29,30)(H,31,32)/t15-,19-,20-/m0/s1
Moexiprilat is the pharmacologically active metabolite of Moexipril. Formation of Moexiprilat is caused by hydrolysis of a Moexipril’s ethyl ester group. Moexiprilat competitively inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the actions of the potent vasoconstrictor angiotensin II and leads to vasodilatation. This agent also prevents angiotensin II-induced aldosterone secretion by the adrenal cortex, thereby promoting diuresis and natriuresis. Moexiprilat showed an extended duration of action owing to a long terminal pharmacokinetic half-life and produced a persistent ACE inhibition.
Originator
Approval Year
Cmax
AUC
Doses
Sourcing
PubMed
Patents
Sample Use Guides
Usual Adult Dose for Hypertension
Initial dose:
-Patients not receiving diuretic therapy: 7.5 mg orally once a day 1 hour before meals
-Patients receiving diuretic therapy: 3.75 mg orally once a day 1 hour before meals
Maintenance dose: 7.5 to 30 mg orally per day in 1 or 2 divided doses 1 hour before meals.
Maximum dose: 60 mg/day
Route of Administration:
Oral
In vitro, moexiprilat (active diacid metabolite of moexipril) was a potent inhibitor of ACE in guinea pig serum as well as on purified ACE from rabbit lung with IC50 values of 2.6 and 4.9 nmol/l, respectively. Both, moexipril and moexiprilat inhibited the angiotensin I (ANG I)-induced contractions of rabbit aorta concentration-dependently.